Dr. Yoshizo Asano and colleagues in Japan report that in measles immunosuppression, cells sensitized to HHV-6B immediate early and early antigen proteins may suppress replication cycles and virus formation, resulting in an “incomplete” subclinical state of reactivation.
We are pleased to announce that with the help of a few HHV-6 specialists, especially Prof. Louis Flamand from Canada, we have generated the monoclonal antibody DR-7.
An international group of experts summarize the significant differences between the two viruses.
A group led by Steven Zeichner has published evidence that suggests the replication of all human herpesviruses can be activated by apoptosis.
Could treatment of HHV-6A co-infections slow AIDS progression?
Japanese group identifies several cytokine and chemokine responses associated with HHV-6B encephalopathy.
HHV-6A and HHV-6B each express distinct chemokines that are uniquely capable of activating key inflammatory cytokines.
CD134, a member of the TNF receptor superfamily, has now been shown as a specific entry receptor for HHV-6B.
A laboratory at the University of Wurzburg has published evidence that Chlamydia trachomatis may induce the activation of ciHHV-6.
A group from France has reported new findings which may help explain the mystery behind the increased rates of HHV-6 reactivation and encephalitis observed among umbilical cord blood transplant (CBT) patients.
A new study has reported that the use of Bortezomib, known commercially as Velcade, may increase the risk of HHV-6 reactivation in myeloma patients undergoing stem cell transplantation.
Findings indicate that HHV-6 infection leads to decreased glutathione production, increased oxidative stress, and induces chlamydial persistence during co-infection
A new study from the University of Munchen in Munich, Germany, has identified a subset of CD8+ T cells that specifically recognize HHV-6B and not HHV-6A.
The International Committee for Taxonomy of Viruses has made it official. HHV-6A and HHV-6B are two distinct viruses, each with their own characteristics and disease associations.
In a recent publication, investigators from the University of Massachusetts reported the first fine characterization of the CD4+ T cell response to HHV-6.